Introduction {#s1}
============

G protein coupled receptors (GPCRs) are integral membrane proteins that are used by cells to convert extracellular signals into intracellular responses, including responses to hormones, neurotransmitters, as well as responses to vision, olfaction and taste signals. These receptors form a superfamily of membrane proteins comprising of five distinct families on the basis of their sequences and structural similarities: rhodopsin (family A), secretin (family B), glutamate (family C), adhesion and Frizzled/Taste2 (Fredriksson et al., [@B40]; Rosenbaum et al., [@B115]). They all share common structural motifs in which seven transmembrane (TM) helices are connected to three extracellular loops and three intracellular loops. However, despite structural similarities, GPCRs have unique combinations of signal-transduction activities involving G protein dependent signaling pathways, as well as G protein-independent signaling pathways and complicated regulatory processes (Azzi et al., [@B8]; Rosenbaum et al., [@B115]; Rajagopal et al., [@B107]).

Numerous studies have presented evidence that implicate GPCRs in the pathogenesis of Alzheimer's disease (AD) and in multiple stages of the hydrolytic processing of amyloid protein precursor (APP), a precursor protein involved in the formation of amyloid plaques found in AD patients' brain (Thathiah and De Strooper, [@B135], [@B136]; Wisely et al., [@B154]). Indeed accumulated data have shown that GPCRs can bind to β-secretase (β-site APP cleaving enzyme 1, BACE1) and γ-secretase which are key enzymes in the hydrolytic processing of APP (Liu et al., [@B77]; Nelson and Sheng, [@B89]; Thathiah et al., [@B137]). However there is currently no cure for AD and the hope for a new treatment has fallen short as the hottest inhibitors targeting BACE1 and γ-secretase haven't been approved by the FDA due to the fact that they are not specific enough as they can also inhibit the normal biological functions of secretases. Therefore, the development of new therapeutic targets aimed at GPCRs could be a promising method to maintain the effect and control the side effects of inhibitors based on biased ligands or allosteric modulators (Rajagopal et al., [@B107]; Nickols and Conn, [@B92]; Violin et al., [@B145]).

The main purpose of this review is to provide an overview of the interaction between GPCRs and BACE1. We will firstly summarize the structures and signaling pathways of GPCRs, then address the reported implication of GPCRs in the pathologic process of AD, focusing on BACE1 related GPCRs, and also discuss the current findings on the regulatory roles of GPCRs in the pathological progression of AD, as well as the implication of GPCRs for pharmaceutical treatment of AD patients.

A Profile of GPCRs {#s2}
==================

GPCRs are encoded by nearly 800 distinct genes in the human genome and form the largest TM receptor family found in humans (Bockaert and Pin, [@B14]). It has been estimated that more than half of all modern drugs are targeted at these receptors (Hopkins and Groom, [@B56]). Nevertheless, these developed drugs only target a very small number of GPCRs, leaving an enormous potential for drug developments within this field (Fredriksson et al., [@B40]).

A GPCR is basically composed of three parts: the extracellular region, the TM region, and the intracellular region. The extracellular region contains N terminus and three extracellular loops (ECL1--ECL3); the TM region contains seven TM α-helices (TM1--TM7); the intracellular region contains three intracellular loops (ICL1--ICL3) and an intracellular amphipathic short α-helix (H8) lying perpendicular to the membrane plane, and the C terminus (Venkatakrishnan et al., [@B144]). In a broad sense, the extracellular region modulates ligand access, the types of which can vary tremendously, ranging from small molecules to large proteins. GPCRs can transduct signals received from messengers such as ions, organic odorants, amines, peptides, proteins, lipids, nucleotides, and even photons (Rosenbaum et al., [@B115]); the TM region forms the structural core, binds to ligands and transduces this information to the intracellular region through conformational changes, and the intracellular region interfaces with cytosolic signaling proteins. The main feature of GPCRs is to interact with G proteins. GPCRs can bind to different isoforms of G proteins: G~s~, G~q/11~, G~i~, G~12/13~ (Ferguson, [@B38]; Ritter and Hall, [@B113]) and activate a number of alternative signaling cascades inside cells, enabling functional diversities (Fredriksson et al., [@B40]). For details of GPCR-dependent signaling pathways see Figure [1](#F1){ref-type="fig"}. The predominant signaling pathway have been revealed from early studies of agonist-activated human β~2~ adrenergic receptor (β~2~AR) binding to G~s~, the stimulatory G protein for adenylyl cyclase. However, it is now known that the β~2~AR couples to the G protein G~i~ (Daaka et al., [@B30]), as well as activating G protein-independent pathways through β-arrestins (Azzi et al., [@B8]), a kind of scaffolding proteins mediating receptor desensitization and internalization (Rajagopal et al., [@B107]), and possibly other cellular signaling proteins. In addition, these activities are further complexified by factors such as GPCR oligomerization, localization to specific membrane compartments and resulting in differences in their lipid-bilayer composition (Rosenbaum et al., [@B115]). It was originally thought that most ligands bound to GPCRs have balanced or unbiased activities for signaling through β-arrestins and G protein pathways, however, some receptor-ligand systems and some allosteric modulators display biased signaling (see "Discussion" Section below), which have important implications for the design of therapeutics (Rajagopal et al., [@B107]).

![**Model of GPCRs mediated signaling pathways.** In classical model, heterotrimeric G proteins (α, β, γ subunits) mediate signal transduction via the receptor. Signal transduction initiated when ligands bind to GPCRs. The resulting conformation change promotes the exchange of GDP for GTP on the Galpha subunit of G proteins. G~s~ activates AC leading to the production of cAMP in cells, then cAMP binds to the regulatory subunit of PKA, regulating the phosphorylation of the GPCR and leading the process of desensitization of GPCR. PKA can regulate the level of CREB (Zeitlin et al., [@B161]) and mediates MAPK ERK pathway (New and Wong, [@B90]). G~q/11~ controls the activity of PLC, which hydrolyzes PIP2 to generate IP3 and DAG. IP3 and DAG in turn lead to an increase in the intracellular concentrations of free Ca^2+^, regulation of NFκB (Arendash et al., [@B5]) and the activation of a number of protein kinases and pathways, including PKC/MAPK/ERK (Ritter and Hall, [@B113]). GPCR activate PI3K/Akt cascades through G~βγ~ (New and Wong, [@B90]). Gi inhibits AC, and G~12/13~ is suggested to activate GSK3 in neuronal cells (Sayas et al., [@B119],[@B120]). GSK3 is involved in tau phosphorylation with regard to AD pathology (Ly et al., [@B80]). And Akt and PKC can inhibit GSK3 activity (New and Wong, [@B90]; Langmead et al., [@B72]). Abbreviations: GPCR(s), G protein-coupled receptor(s); GDP, guanosine diphosphate; GTP, guanosine triphosphate; AC, adenyl cyclase; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; CREB, cAMP response element-binding protein; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; PLC, phospholipase C; PIP2, phosphatidylinositol 4, 5-bisphosphate; IP3, inositol triphosphate; DAG, diacylglycerol; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; PKC, protein kinase C; PI3K, phosphotidylinositol 3-kinase; Akt, protein kinase B; GSK3, glycogen synthase kinase-3; AD, Alzheimer's Disease.](fnagi-08-00058-g0001){#F1}

To provide insights into the structural and functional diversity of GPCRs, the resolution of structure is necessary. However they have been proven to be difficult to obtain, typically requiring considerable time and investment (Venkatakrishnan et al., [@B144]). Indeed, GPCRs are naturally produced but only in very small quantities and often have short half-lives until degradation occurs in cells. Since GPCRs are membrane-bound proteins, indicating that they contain hydrophobic parts, thus experimental determination of their 3D structures is still an extremely difficult task (Warne et al., [@B150]). The first GPCR to yield molecular structure data was unliganded bovine rhodopsin purified from native tissue because of its high natural abundance in retina (Palczewski et al., [@B101]). We summarized the resolved GPCRs in Table [1](#T1){ref-type="table"}. Data were collected from Protein Data Bank.

###### 

**GPCRs that have resolved crystal structures in a timeline**.

  Year   Proteins
  ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  2000   Bovine rhodopsin (1F88), Palczewski et al. ([@B101])
  2007   Human **β**~2~AR (2RH1), Rasmussen et al. ([@B108])
  2008   Turkey **β**~1~AR (2VT4), Warne et al. ([@B150]); Squid rhodopsin (2Z73), Murakami and Kouyama ([@B85]); Human A~2A~ AR (3EML), Jaakola et al. ([@B58])
  2010   Human CXCR4 (3ODU), Wu et al. ([@B155]); Human D3R (3PBL), Chien et al. ([@B25])
  2011   Human H~1~R (3RZE), Shimamura et al. ([@B124])
  2012   Human M~2~ AchR (3UON), Haga et al. ([@B46]); Human S1PR (3V2Y), Hanson et al. ([@B47]); Human M~3~ AChR (4DAJ), Kruse et al. ([@B71]); Human KOR (4DJH), Wu et al. ([@B156]); Mouse MOR (4DKL), Manglik et al. ([@B82]); Human N/O FQR (4EA3), Thompson et al. ([@B139]); Mouse DOR (4EJ4), Granier et al. ([@B45]); Rat NTSR1 (4GRV), White et al. ([@B153]); Human CXCR1 (2LNL), Park et al. ([@B103]); Human PAR1 (3VW7), Zhang et al. ([@B162])
  2013   Human 5-HT~2B~R (4IB4), Wacker et al. ([@B146]); Human 5-HT~1B~R (4IAR), Wang et al. ([@B148]); Human SMOR (4JKV), Wang et al. ([@B147]); Human CRFR1 (4K5Y), Hollenstein et al. ([@B55]); Human GCGR (4L6R), Siu et al. ([@B126]); Human CCR5 CR Tan et al. ([@B129])
  2014   Human GluR1 (4OR2), Wu et al. ([@B157]); Human P2YR12 (4NTJ), Zhang et al. ([@B165]); Human GluR5 (4OO9), Doré et al. ([@B33]); Human GPR40 (4PHU), Srivastava et al. ([@B127])
  2015   Human OX2 (4S0V), Yin et al. ([@B160]); Human DOR (4RW4), Fenalti et al. ([@B37]); Human P2YR1 (4XNW), Zhang et al. ([@B163]); Human AT~1~R (4YAY), Zhang et al. ([@B164])

*Abbreviations: GPCRs, G protein-coupled receptors; β~1~/β~2~AR, β~1~/β~2~ adrenergic receptor; A~2A~ AR, adenosine A~2A~ receptor; CXCR4, C-X-C chemokine receptor type 4; D~3~R, D~3~ dopamine receptor; H~1~R: histamine H~1~ receptor; M~2~/M~3~ AChR, M~2~/M~3~ muscarinic acetylcholine receptor; S1PR, sphingosine-1 phosphate receptor; K/M/DOR, kappa/mu/delta opioid receptor; N/O FQR, nociceptin/orphanin FQ receptor; NTSR1, neurotensin receptor type 1; CXCR1, CXC chemokine receptor 1; PAR1, protease-activated receptor; 5-HT~1B/2B~R, 5-hydroxytryptamine receptor type 1B/2B; SMOR, smoothened receptor; CRFR1, Corticotropin-releasing hormone receptor 1; GCGR, glucagon receptor; CCR5 CR, C-C chemokine receptor type 5; GluR1/5, glutamate receptor type 1/5; P2YR1/12, purinergic G protein-coupled receptor 1/12; GPR40, G protein-coupled receptor 40; OX~2~, Orexin receptor type 2; AT~1~R, Angiotensin II type 1 receptor*.

GPCRs and AD {#s3}
============

AD is the most common neurodegenerative disorder afflicting around 24.0 million people worldwide, the morbidity rate of which rises dramatically as people get older (Erb et al., [@B35]). The pathological hallmark of AD is the extracellular deposition of beta amyloid peptide (Aβ), the oligomeric soluble forms of which are believed to be a key point for neuronal dysfunction, synapse loss, neurofibrillary degeneration (Das et al., [@B31]). Aβ comes from the amyloidogenic cleavage of APP, for details, see Figure [2](#F2){ref-type="fig"}.

![**Cleavage of amyloid precursor protein (APP).** APP processes two different hydrolysis pathways: amyloidogenic pathway and non-amyloidogenic pathway. Sequential cleavage of APP by α-secretase and γ-secretase generates a soluble amino terminal ectodomain of APP (sAPPα), the carboxy terminal fragment C83, APP intracellular domain (AICD) and a short fragment p3. There is no production of beta amyloid peptide (Aβ) from this pathway. Sequential cleavage of APP by β-secretase (BACE1) and γ-secretase generates sAPPβ, C99, AICD and Aβ (Thathiah and De Strooper, [@B136]).](fnagi-08-00058-g0002){#F2}

Many reports presented evidence that GPCRs were related to AD (Blalock et al., [@B13]; Thathiah and De Strooper, [@B135], [@B136]; Conn et al., [@B29]; Huang et al., [@B57]). Blalock et al. ([@B13]) published that an alteration of the gene expression profile occurs in AD patients' postmortem brains obtained by cDNA microarray analysis. Analysis of the gene expression profile of AD patients with different pathological severity vs. normal age-matched controls showed that the levels of transcripts from a number of GPCR genes changed, among which were inflammation associated GPCRs, hormone receptors, neurotransmitter receptors and some others. For example, arginine vasopressin receptor 1A, dopamine receptor D2 (D2R), metabotropic glutamate receptor type 6 (mGluR6), histamine H4 receptor, G protein-coupled receptor 2 (GPR2) and some others were upregulated; while cannabinoid receptor type 1, gamma-aminobutyric acid receptors, 5-hydroxytryptamine receptor 1E/2A, parathyroid hormone 2 receptor, orphan G protein-coupled receptor 22 (GPR22) and some others were downregulated (Blalock et al., [@B13]). Given that the change of expression levels of GPCRs would have an effect on the related biological processes, these observations suggested a potential role of GPCR in the pathological progression of AD, which requires further investigation (Blalock et al., [@B13]). Until now, numerous promising works have been done to connect GPCRs and AD pathology based on three hypotheses: the Cholinergic hypothesis, the Tau hypothesis and the Amyloid hypothesis (Thathiah and De Strooper, [@B135], [@B136]; Wisely et al., [@B154]).

We summarize the GPCRs involved in AD in Table [2](#T2){ref-type="table"}. Most GPCRs in family A are classified as binding small ligands within their TM core. Family B can bind mid-size peptide hormones with their deep and open V-shaped crevice. Family C is characterized by a large N-terminal domain which is the recognition site for ligands (Katritch et al., [@B63]). Besides, matching electrostatic properties among ligands and binding pocket allows the discrimination between ligands of a wide range of sizes. For example Kappa opioid receptor has highly acidic patches at the extracellular side, which most likely interacts with the basic C-terminus of dynorphin; in contrast, Mu opioid receptor lacks negative surface potential reflecting the uncharged nature of enkephalins (Manglik et al., [@B82]). Serine and threonine residues in the C-terminal region and a serine-rich sequence in ICL3 are potential sites for phosphorylation. A recent research verified that site mutation at ICL3 on the corticotrophin releasing factor receptor 1 (CRFR1) decreases the interaction between CRFR1 and γ-secretase, and blocks CRF-induced increase in total Aβ and Aβ40 but not Aβ42 (Park et al., [@B102]).

###### 

**GPCRs involved in AD**.

  GPCRs                 Families   Relation to AD
  --------------------- ---------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  M1 AChR               Family A   (sAPP↑, Aβ↓), Nitsch et al. ([@B94]); Jones et al. ([@B60]); and Jiang et al. ([@B59]); (sAPP↑), Buxbaum et al. ([@B18]); (BACE1↑), Züchner et al. ([@B168]); (M1 AChR knock-out transgenic mice APP~Swedish/Indiana~, Aβ↑), Davis et al. ([@B32]); (BACE1↓, Aβ↓), Caccamo et al. ([@B19])
  M2 AChR               Family A   (BACE1↓), Züchner et al. ([@B168])
  M3 AChR               Family A   (sAPP↑, Aβ↓), Nitsch et al. ([@B94]); ( BACE1↑), Züchner et al. ([@B168])
  mGluR1                Family C   (C83, C99, Aβ~40~↑), Kim et al. ([@B66]); (sAPP↑), Lee et al. ([@B74]); Kirazov et al. ([@B67]) and Nitsch et al. ([@B93])
  mGluR2                Family C   (tau phosphorylation↑), Lee et al. ([@B73]); (C83, C99, Aβ~42~↑), Kim et al. ([@B66])
  mGluR3                Family C   (C83, C99, Aβ~42~↑), Kim et al. ([@B66])
  mGluR5                Family C   (C83, C99, Aβ~40~↑), Kim et al. ([@B66])
  5-HT~2~R              Family A   (sAPP↑, Aβ↓), Nitsch et al. ([@B95]); (Aβ↓), Arjona et al. ([@B7])
  5-HT~4~R              Family A   (sAPPα↑, Aβ↓), Robert et al. ([@B114]); Giannoni et al. ([@B42]); Tesseur et al. ([@B134]); and Pimenova et al. ([@B105])
  5-HT~6~R              Family A   (Improved cognition and memory), Upton et al. ([@B142]); Maher-Edwards et al. ([@B81]); Rossé and Schaffhauser ([@B116]); and Benhamú et al. ([@B12])
  DOR                   Family A   (Aβ↓), Teng et al. ([@B132]) and Cai and Ratka ([@B20])
  Adrenergic Receptor   Family A   (Aβ↑), Ni et al. ([@B91]) and Chen et al. ([@B23]); (tau phosphorylation↑), Branca et al. ([@B16]) and Wisely et al. ([@B154])
  ATR                   Family A   (Tau phosphorylation and neurodegeneration↑), (AbdAlla et al., [@B1], [@B2]); (memory↓), Ongali et al. ([@B99])
  Adenosine Receptor    Family A   (Aβ↓), Canas et al. ([@B21]); Espinosa et al. ([@B36]); Giunta et al. ([@B44]); Nagpure and Bian ([@B88]); and Orr et al. ([@B100]); (BACE1↓, Aβ↓), Arendash et al. ([@B6])
  CXCR2                 Family A   (Aβ↑), Bakshi et al. ([@B11]); Bakshi et al. ([@B9]); Bakshi et al. ([@B10])
  CXCR3                 Family A   (plaque↑), Krauthausen et al. ([@B70])
  CRFR1                 Family B   (Aβ↓), Justice et al. ([@B61]); (tau hyperphosphorylation↓), Carroll et al. ([@B22]) and Rissman et al. ([@B112]); (hippocampal synaptophysin level↑), Scullion et al. ([@B121])
  PACR1                 Family B   (sAPPα↑), Kojro et al. ([@B69]); (cognition↑), Rat et al. ([@B109]) and Yang et al. ([@B159])
  GPR3                  Family A   (Aβ↑), Thathiah et al. ([@B138]) and Nelson and Sheng ([@B89])
  P2Y receptor          Family A   (Aβ↑), Ajit et al. ([@B3]) and Erb et al. ([@B35])
  CX3CR1                Family A   (amyloid plaque↓), Lee et al. ([@B75]); Liu et al. ([@B78]); Cho et al. ([@B26]) and Condello et al. ([@B27])
  CCR2                  Family A   (Aβ↓); El Khoury et al. ([@B34])

*Abbreviations: GPCRs, G protein-coupled receptors; AD, Alzheimer's Disease; M~1~/ M~2~/M~3~ AChR, M~1~/ M~2~/M~3~ muscarinic acetylcholine receptor; mGluR1/2/3/5, metabotropic glutamate receptor type 1/2/3/5; 5-HT~2/4/6~R, 5-hydroxytryptamine receptor type 2/4/6; DOR: δ opioid receptor; ATR, angiotensin receptor; CXCR2/3, CXC chemokine receptor 2/3; CRFR1, corticotrophin releasing factor receptor 1; PACR1, Pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type I; GPR3, G protein-coupled receptor 3; P2Y receptor, purinergic G protein-coupled receptor; CX3CR1, CX3C chemokine receptor type 1; CCR2, C-C chemokine receptor type 2; sAPP, soluble amino-terminal ectodomain of amyloid precursor protein; sAPPα, soluble amino terminal ectodomain of APP cleaved by α-secretase; Aβ, beta amyloid peptide; Aβ~40/42~, 40/42-amino acid beta amyloid peptide; BACE1, beta secretase; C83, 83-amino acid carboxy-terminal fragment; C99, 99-amino acid carboxy-terminal fragment*.

GPCRs and BACE1 {#s4}
===============

BACE1, a 501 amino acid type 1 TM aspartic protease related to the pepsin family, initiates Aβ generation and the resultant cerebral amyloidosis: deposition of Aβ (for details, see Figure [2](#F2){ref-type="fig"}). BACE1 catalytic domain contains two signature aspartic protease motifs (Asp-Thr/Ser-Gly-Ser/Thr) that form the active site of the enzyme and are oriented in the lumen of acidic intracellular compartments for cleaving the β-secretase site of APP. The highest concentrations of BACE1 can be found in neurons. With the correct sequence specificity and at acidic pH optimum for enzymatic activity, BACE1 undertakes processing of APP, and increases Aβ generation (Yan and Vassar, [@B48]). BACE1 is predominantly localized in the tans Golgi network (TGN) and endosomes. These acidic endosome compartments provide a low pH environment, which is more favorable for BACE1 activity (Das et al., [@B31]). In the AD brain, the activity of BACE1 has been shown to be up-regulated, but not its mRNA levels (Yang et al., [@B158]). Several proteins, such as translation initiation factor eIF2α (O'Connor et al., [@B96]), Golgi-localized γ-ear-containing adenosine diphosphate (ADP)-ribosylation factor binding proteins (GGAs; He et al., [@B50]), glycogen synthase kinase 3 (GSK3; Ly et al., [@B80]), the reticulon/Nogo family of proteins (He et al., [@B49]), and sortilins (Okada et al., [@B98]), are implicated in the regulation of BACE1, but the mechanisms, as well as their putative coordinated actions, remain unclear. In the GPCR superfamily, M1 AChR (Jiang et al., [@B59]), δ-opioid receptor (DOR; Teng et al., [@B132]), A~2A~ receptor (Arendash et al., [@B6]), are reported to regulate the activity of BACE1. GPCR regulating proteins, such as GPCR-associated sorting proteins (GASPs; Mishra and Heese, [@B84]), small G proteins such as Rabs (Teng et al., [@B132]; Buggia-Prévot et al., [@B17]) and ADP-ribosylation factor 6 (ARF6; Sannerud et al., [@B118]) are also revealed to mediate BACE1 activity.

Muscarinic Acetylcholine Receptor {#s4-1}
---------------------------------

### Introduction to Muscarinic Acetylcholine Receptor {#s4-1-1}

The muscarinic acetylcholine receptors are members of the family A GPCRs that are synthesized by cholinergic cells. They are widely expressed in the central nervous system where they control a variety of neuronal functions (Langmead et al., [@B72]). The five subtypes of muscarinic acetylcholine receptor (mAChR) are generally divided into two groups based on signal transduction (Wess et al., [@B152]). M~1~, M~3~ and M~5~ mAChRs can activate phospholipase C (PLC) and mobilize intracellular calcium through G~q/11~, which is critical in neuronal communication and synaptic plasticity. While M~2~ and M~4~ mAChRs are coupled to G~i~ and then inhibit adenylate cyclase activity (Langmead et al., [@B72]) as well as several ion channels such as N-methyl-D-aspartate receptor (NMDAR; Salter and Kalia, [@B117]) and calcium channels (Zhou et al., [@B167]), leading to the reduction of cyclic adenosine monophosphate (cAMP), the inhibition of voltage-gated Ca^2+^ channels, and the increasing efflux of K^+^, in general, leading to inhibitory effects (Odagaki et al., [@B97]). mAChRs and ligand-gated ion channel nicotinic (nAChR) together can mediate the actions of acetylcholine (ACh). Both are important neurotransmitter receptors involved in learning and memory (Thathiah and De Strooper, [@B135]). Actually, commercial therapies for the treatment of AD approved by the FDA are mainly acetylcholinesterase inhibitors (AChEI) that are designed to boost levels of ACh. Since 1992, when researchers found that activation of M~1~ and M~3~ AChR can increase the release of soluble amino terminal ectodomain of APP cleaved by α-secretase (sAPPα). In addition, mAChRs have been intensively studied and revealed that the increase of sAPPα was accompanied by a decreased release of Aβ, suggesting that normal cholinergic activity may suppress the formation of potentially amyloidogenic derivatives (Nitsch et al., [@B94]). It was speculated that mAChR regulates APP release by protein kinase C (PKC) activation or an interaction of diacylglycerol and calcium released from internal pools by inositol triphosphate (IP3; Nitsch et al., [@B94]). The predominant mAChR in the CNS is subtype 1, which is located in the cerebral cortex and hippocampus, areas known to be vital for learning and memory and to be the location where amyloid plaques form, resulting in neuron loss. As a consequence, M1 mAChR agonists has been suggested as a promising novel approach to AD therapy (Langmead et al., [@B72]; Conn et al., [@B28]; Melancon et al., [@B83]). Xanomeline is a selective agonist of M~1~/M~4~ subtype, which provides the most significant human data for treatment of AD (Bodick et al., [@B15]). Despite the fact that it failed during phase-II clinical trial due to serious side-effects, Xanomeline has been shown to have reasonable efficacy to improve learning and short-term memory in AD patients (Conn et al., [@B28]).

### BACE1 Related Muscarinic Acetylcholine Receptors {#s4-1-2}

Studies have demonstrated that mAChR can mediate the level of BACE1 (Züchner et al., [@B168]; Jiang et al., [@B59]). The activation of M~1~ and M~3~ mAChRs in SK-SH-SY5Y neuroblastoma cell line by talsaclidine, a M~1~/M~3~-selective mAChR agonist, could up-regulate BACE1 in a dose-dependent way after 3 h treatment. In contrast, BACE1 expression was down-regulated by the activation of M~2~ mAChR (Züchner et al., [@B168]). However, results are controversial (Caccamo et al., [@B19]; Jiang et al., [@B59]). Caccamo et al. ([@B19]) investigated the therapeutic efficacy of selective M~1~ mAChR agonist AF267B in the 3 × Tg-AD model mice (human APP Swedish mutation, APP~Swe~, tau~P30L~, mutant PS1~M146V~ knockin) and found a significant decrease in BACE1 levels in the brain of AF267B treated mice vs. untreated 3 × Tg-AD mice. Conversely, administration of dicyclomine, an M~1~ mAChR antagonist, led to a notable increase in BACE1 levels compared with phosphate-buffered saline (PBS)-injected mice (Caccamo et al., [@B19]). A recent data also showed a dramatical decrease of BACE1 protein levels instead of the mRNA levels after over-expression of M~1~ mAChR into human embryonic kidney (HEK)-APP~Swe~ cells, a HEK cell line stably expressing human APP Swedish mutations (Jiang et al., [@B59]). This process is accompanied with a rise of sAPPα and a fall of Aβ, while there is no effect on the level of full-length APP. The authors confirmed the interaction between M~1~ mAChR and BACE1 by yeast two-hybrid and co-immunoprecipitation experiments. They further silenced M~1~ mAChR and the endogenous BACE1 was markedly increased (Jiang et al., [@B59]).

Opioid Receptor {#s4-2}
---------------

### Introduction to Opioid Receptor {#s4-2-1}

The opioid system modulates several physiological processes, including analgesia, the stress response, the immune response and the neuroendocrine function. Opioid receptors and opioid peptides, vulnerable to AD, are widely expressed in the central nervous system, including hippocampus and cortex, the brain regions crucial for cognition. They play important roles in synaptic activation, learning and memory. Administration of opioid antagonists has been found to significantly improve the memory of animals (Gallagher et al., [@B41]); thus, in 1980s, the opioid antagonist naloxone, which was approved for the treatment of opioid overdose by the FDA in 1971, was used in a double-blinded placebo-controlled clinical study to test its potential effect on improving cognitive functioning in individuals with probable AD (Reisberg et al., [@B110]). However, later studies have failed to support the efficacy of the nonselective antagonists naloxone or naltrexone in AD (Tariot et al., [@B131]; Henderson et al., [@B53]). Given the distinct and even opposing roles of DOR, κ-opioid receptor (KOR), and μ-opioid receptor (MOR) in modulating animal behaviors, such as response of locomotion, level of anxiety, depressive-like behavior or alcohol intake in different opioid receptor knockout mice (Kieffer and Gavériaux-Ruff, [@B65]), the overlap between the distribution of opioid receptors and the location of amyloid plaques in AD patients led us to postulate a possible role of these three opioid receptors in the pathology of AD.

### BACE1 Related Opioid Receptors {#s4-2-2}

Previous reports have shown that altered cell signaling of opioid receptors is related to abnormal Aβ production and AD pathogenesis (Reisberg et al., [@B110]; Tariot et al., [@B131]; Henderson et al., [@B53]; Ni et al., [@B91]). Teng et al., [@B132] over-expressed DOR in HEK293T cell line and performed the fluorogenic substrate assay to directly evaluate the effect of DOR on secretase activities and found that 30 min after stimulation by DOR agonist, BACE1 and γ-secretase activities were enhanced to 143% and 156%, respectively, while the activity of α-secretase was not affected. Pretreatment with DOR selective antagonist naltrindole (NTI), on the other hand, blocked the enhancement of BACE1 and γ-secretase activities by DOR agonist, indicating that secretase activity enhancement depends on DOR activation (Teng et al., [@B132]). Chronic treatment of APP/PS transgenic AD model mice with NTI alleviated Aβ pathology and improved cognitive deficits in spatial reference memory by reducing activities of endogenous BACE1 and γ-secretase without any changes in APP expression levels or Aβ clearance (Teng et al., [@B132]).

Adenosine Receptor {#s4-3}
------------------

### Introduction to Adenosine Receptor {#s4-3-1}

Adenosine is found in all cells including glia and neurons, and plays important roles in the regulation of synaptic transmission and neuronal excitability in the central nervous system. Functional and molecular studies made it possible to classify adenosine receptors as A~1~, A~2A~, A~2B~, and A~3~ subtypes (Ribeiro and Sebastião, [@B111]). A~1~ receptors are highly enriched in the CA1 region of hippocampus in a normal healthy brain. A change in the pattern of A~1~ receptor expression has been found in AD patients when compared with age-matched control brains (Angulo et al., [@B4]). In addition, activation of A~1~ receptors could lead to the production of soluble APP, which was confirmed by the use of A~1~-selective antagonist DPCPX (Angulo et al., [@B4]). Studies also revealed that A~1~ receptors mediate tau phosphorylation, another key factor for pathogenesis of AD besides Aβ, and its translocation towards the cytoskeleton of neuroblastoma cells (Angulo et al., [@B4]; Giunta et al., [@B44]). A marked increase in A~1~ receptor immunoreactivity has been found in degenerating neurons with neurofibrillary tangles and in dystrophic neurites of Aβ plaques in the hippocampus and frontal cortex of AD (Angulo et al., [@B4]). Significant co-localizations of A~1~ receptors and Aβ in senile plaques, as well as of A~1~ receptors and tau in neurons with tau deposition, have been found (Angulo et al., [@B4]; Giunta et al., [@B44]). The A~2A~ receptor is also expressed in the brain, where it has important roles in the regulation of glutamate and dopamine release, making it a potential therapeutic target for the treatment of neuronal diseases. A~2A~ receptors have low expression in healthy brain but this pattern of expression and functionality can be changed in pathological conditions.

### BACE1 Related Adenosine Receptors {#s4-3-2}

Arendash et al. reported a decrease of BACE1 and PS1 expression level in APP transgenic mouse hippocampal tissue after long term administration of caffeine, a non-selective A~1~ and A~2A~ adenosine receptor antagonist, to APP~Swe~ transgenic mice. Caffeine treatment also improved cognition and reduced Aβ~40~ and Aβ~42~ generation of APP~Swe~ mice (Arendash et al., [@B6]). The authors then further provided evidence that caffeine treatment can reverse cognitive impairment and they developed insight into possible mechanisms involved in BACE1 suppression by caffeine (Arendash et al., [@B5]; Zeitlin et al., [@B161]).

GPCR Regulating Proteins {#s4-4}
------------------------

### Small GTPase {#s4-4-1}

Small GTPase constitute a superfamily consisting of more than 100 members. This superfamily is structurally classified into at least five families: the Ras, Rho/Rac/Cdc42, Rab, Sar1/ARF, and Ran families (Takai et al., [@B128]). Some Rabs are expressed ubiquitously in human tissues, whereas others are tissue-specific. Within cells, they are localized to the cytosolic face of distinct intracellular membranes (Pfeffer, [@B104]; Nagano et al., [@B87]). Functional loss of the Rab pathways has been implicated in a variety of diseases, Rab5 and Rab7, which control early and late endosome fusion respectively, are selectively up-regulated in hippocampal neurons of individuals with mild cognitive impairment and AD (Ginsberg et al., [@B43]). In the team of Pei G, they observed the colocalization of Rab7 and BACE1, Rab7 and BACE1/PS1 complex (Teng et al., [@B132]). Further data from RNAi screening of all human Rab-GTPase associate Rab11 with late onset AD (Udayar et al., [@B140]). Recently, Buggia et al. reported that Rab11 is critical for axonal sorting of BACE1, since BACE1 shows in Rab11 positive endosomes, and impairment of Rab11 function leads to a diminution of total and endocytosis BACE1 in axons (Buggia-Prévot et al., [@B17]). Rab11 was revealed to colocalize with BACE1 by direct visual images (Das et al., [@B31]). Also ARFs are a family of small GTPases that are involved in various aspects of membrane trafficking events. ARF6 is demonstrated to mediate the endosomal sorting of BACE1. Furthermore, the sorting of newly internalized BACE1 from ARF6-positive towards Rab GTPase 5 (Rab5)-positive early endosomes depends on the carboxyterminal short acidic cluster-dileucine motif of BACE1 (Sannerud et al., [@B118]). Ras homolog enriched in brain (Rheb) was demonstrated to regulate BACE1 stability and activity by reducing the half-life of BACE1 in a GTP-dependent manner (Shahani et al., [@B123]).

### GPCR-Associated Sorting Protein {#s4-4-2}

GPCR-associated sorting protein (GPRASP family protein) has been shown to preferentially sort a number of native GPCRs to the lysosome for degradation after endocytosis. p60TRP, also known as GASP3 or BHLHB9, is a kind of GPRASP. P60TRP is localized in both the cytoplasm and the nucleus of cells and has been predominantly observed in the CNS, particularly in the brain. Among the many distinguishing features of p60TRP, one of the most noteworthy is that it contains a potential myc-type basic helix-loop-helix (bHLH) domain at its C-terminus; this domain is a protein structural motif that characterizes a family of transcription factors (Heese, [@B51]). Since 2004, Heese Klaus with the lab members have discovered p60TRP gene as a potential rescue factor against cell death by applying a death trap method (Heese et al., [@B52]). Increased expression of p60TRP induces the dephosphorylation of APP, which inhibits BACE1 activity and causes reduced APP intracellular domain (AICD) signaling in p60TRP-overexpressing cells (Mishra and Heese, [@B84]).

Discussion {#s5}
==========

How do GPCRs regulate the levels of BACE1? Despite countless research studies being performed, the answer remains to be elucidated. However, the available documents provide us insights to the role of GPCRs in mediating BACE1 by mechanisms that fall into the following categories: (i) GPCRs activation stimulates G protein-dependent signaling pathway, which finally alters the expression level of BACE1; (ii) GPCRs activation mediates the degradation of BACE1; and (iii) GPCRs activation regulates the trafficking of BACE1.

Impact of GPCRs Signaling Pathway on BACE1 Expression {#s5-1}
-----------------------------------------------------

The classical G protein signaling pathway (see Figure [1](#F1){ref-type="fig"}) is considered to be an explanation for the regulation of BACE1 and other key proteins in AD (Thathiah and De Strooper, [@B136]). The concurrence of changes in some molecules in the pathway and changes in key proteins in AD after activation of GPCRs seems to be more than coincidental.

A previous study suggested that the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is involved in the regulation of BACE1 by M~1~ mAChR (Sinha et al., [@B125]). One effect of MAPK/ERK activation is to alter the translation of mRNA to proteins. Züchner et al. showed that agonists binding to M~1~-/M~3~- mAChR can up-regulate BACE1 expression through activation of both PKC and MAPK signaling cascades. In contrast, studies have shown BACE1 expression is down-regulated by the activation of M~2~- mAChR- and protein kinase A (PKA)-mediated pathways (Züchner et al., [@B168]). Studies also showed that caffeine treatment can significantly increase PKA activity in Tg mice and striatum of APP~Swe~ mice (Arendash et al., [@B5]; Zeitlin et al., [@B161]). The author proposed that enhanced PKA activity inhibits cRaf-1 (a proto-oncogene serine/threonine-protein kinase) by phosphorylation at serine259, decreasing nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) activity and the expression of NFκB-controlled genes such as BACE1 in the hippocampus of treated AD Tg mice (Arendash et al., [@B5]). In addition, the results showed that caffeine increases cAMP response element-binding protein (CREB) phosphorylation at Ser133 in the striatum and decreases c-Jun N-terminal kinase (JNK)/ERK phosphorylation in the striatum and cortex of APP~Swe~ mice (Zeitlin et al., [@B161]). And Caccamo et al. ([@B19]) demonstrated a significant decrease in BACE1 levels in the brain of AF267B treated mice and compared to untreated 3 × Tg-AD mice, while a dramatic increase in BACE1 levels in the brain of dicyclomine treated mice. Accompanied with the changes of BACE1, a marked rise of phosphorylated ERK in the brains of AF267B treated mice, and a significant reduction of that in the brains of dicyclomine treated mice, in comparison with PBS-treated mice, while levels of ERK were not changed in the brain of AF267B or dicyclomine treated mice (Caccamo et al., [@B19]). This is consistent with the fact that phosphorylated ERK represents functional ERK. Paradoxically, recent data suggested M~1~ mAChRs can interact with BACE1 and decrease BACE1 to reduce Aβ, in which process ERK and phosphoinositide 3-kinase (PI3K) signaling pathway is not involved (Jiang et al., [@B59]). Also, G protein pathway is not involved in the DOR activation-induced rise of BACE1 (Teng et al., [@B132]).

Furthermore, comparable findings were observed regarding γ-secretase and GPCRs (Ni et al., [@B91]; Thathiah et al., [@B138]). Pei G and his team ruled out the involvement of β~2~-adrenergic receptor (β~2~-AR)-induced G protein-dependent signaling pathway. Initially, they used β~2~-AR mutants, which could not activate G protein, and found that the uncoupling of the receptors with G protein did not affect the enhancement of γ-secretase. Then they treated cells with some reagents that mimic G protein activation and found none of them could enhance γ-secretase activity (Ni et al., [@B91]). Thathiah et al. ([@B138]) demonstrated that the orphan G protein-coupled receptor 3 (GPR3) could increase Aβ generation by enhancing γ-secretase activity independent of GPCR signaling pathway with similar methods. GPR3, G protein-coupled receptor 6 (GPR6) and G protein-coupled receptor 12 (GPR12) shared signaling triggered by sphingosine-1 phosphate receptor (S1PR; Uhlenbrock et al., [@B141]). They are involved in cAMP signaling pathway (Hinckley et al., [@B54]; Tanaka et al., [@B130]).

Impact of GPCRs on BACE1 Degradation {#s5-2}
------------------------------------

BACE1 has been reported to be degraded by the lysosomes and ubiquitin-proteasome pathway (Qing et al., [@B106]; Koh et al., [@B68]; Kang et al., [@B62]; Wang et al., [@B149]), and accelerating BACE1 degradation by ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) reduces 99-amino acid carboxy-terminal fragment (C99) and Aβ production (Zhang et al., [@B166]). Researchers from a lab of Xiamen University observed the increase and decrease of BACE1 after activation and inhibition of M~1~ mAChR, meanwhile the mRNA levels of BACE1 remained stable. They suggested that the effects of BACE1 by M~1~ mAChR is probably mediated by its degradation (Jiang et al., [@B59]). When cells were treated with proteasome inhibitor lactacystin, it was shown that over-expression of M~1~ mAChR could result in a marked increase in the level of ubiquitinated BACE1. When cells were treated with a lysosome inhibitor NH~4~Cl, it was found that BACE1 levels also increases, but no differences between cells of M~1~ mAChR over-expression treatment, suggesting that BACE1 could be degraded by both lysosome and ubiquitin-proteasome pathway, while M1 mAChR-mediated BACE1 degradation is mainly through ubiquitin-proteasome pathway (Jiang et al., [@B59]). Whereas the details about how GPCRs regulate BACE1 degradation needs further investigation.

Impact of GPCRs on BACE1 Trafficking {#s5-3}
------------------------------------

BACE1 cycles between the Golgi apparatus and the plasma membrane, traveling through endosomes on the way. Substantive evidence indicated that APP processing by BACE1 is dependent on the intracellular trafficking of this enzyme (He et al., [@B49]; Tesco et al., [@B133]; Sannerud et al., [@B118]; Chia et al., [@B24]; Buggia-Prévot et al., [@B17]). For example, BACE1 can interact with reticulon/Nogo proteins, whose increased expression can block BACE1 in the endoplasmic reticulum (ER) that has a neutral pH environment and thus inhibiting BACE1 activity in Aβ generation (He et al., [@B49]; Murayama et al., [@B86]). Depletion of GGA proteins increases the accumulation of BACE1 in acidic early endosomes resulting in enhanced BACE1 stability and APP cleavage (Tesco et al., [@B133]). Nonetheless, knowledge of the intracellular trafficking pathway of internalized BACE1 remains in doubt.

### Alteration of BACE1 in Plasma Membrane {#s5-3-1}

Many GPCRs, BACE1, γ-secretase, and Aβ generation are localized in lipid raft (Thathiah et al., [@B138]; Teng et al., [@B132]; Park et al., [@B102]). Researches have revealed that GPCRs activation could increase the distribution of BACE1 and γ-secretase in lipid rafts (Teng et al., [@B132]). What's more, they proposed a model of GPCR/BACE1/γ-secretase complex, based on the results of immunoprecipitation experiments. They then verified that disruption of lipid raft by removing cholesterol from the cells could significantly reduce the interaction between DOR and BACE1 or γ-secretase, indicating that the association is dependent on the integrity of lipid raft (Teng et al., [@B132]). Likewise, GPR3 appears to promote the trafficking of γ-secretase to the cell surface and increased localization in detergent-resistant membranes (DRMs), which eventually leads to an increase in Aβ generation (Thathiah et al., [@B138]).

### Alteration of BACE1 Internalization {#s5-3-2}

Clathrin-mediated endocytosis is the primary process of GPCRs and APP internalization, while internalization of BACE1 occurs at a slower bulk flow rate (Ni et al., [@B91]; Sannerud et al., [@B118]). Pei G and his group has confirmed that DOR activation leads to an enrichment of BACE1 and γ-secretase in endocytic compartments. They suspected whether DOR could direct the endocytosis of secretases, so they performed confocal fluorescence time-lapse microscopy with HEK293T cells expressing fluorescently tagged BACE1 and PS1 (catalytic subunit of γ-secretase) together with tagged DOR, they indeed detected a strong colocalization of the three proteins (Teng et al., [@B132]).

### Alteration of BACE1 in Endosomes {#s5-3-3}

Mechanistic studies have revealed that activated DOR can facilitate the endocytic sorting of secretases for APP endoproteolysis and enhance Aβ production. A dysfunction of the receptor can retard the endocytosis of BACE1 and γ-secretase and thus the production of Aβ (Teng et al., [@B132]). The authors further conceived two chimeric receptors to test whether different receptor endocytic sorting could coordinate with BACE1 and γ-secretase intracellular trafficking. Results indicated that different receptors regulate specific substrates (Teng et al., [@B132]).

The shedding of APP by BACE1 appears to mainly occur in early endosomal compartments based on the colocalization with Rab5, a marker for early endosomes. In this case, the factors promoting APP or BACE1 internalization to endosomes can enhance Aβ generation. Reversely, blocking their meeting decreases Aβ levels (Sannerud et al., [@B118]). The small GTPase ARF6 was reported to be an important modulator of BACE1 sorting. The authors created an ARF6 mutant locked in its ADP-bound state to evaluate the effect on BACE1 and APP sorting, and found that it blocks the delivery of BACE1 to early endosomes, suggesting that the GTP hydrolysis of ARF6 is required for the sorting of BACE1 (Sannerud et al., [@B118]). They further confirmed that the dileucine motif in the BACE1 carboxyterminal tail is required for the sorting of BACE1 to early endosomes (Sannerud et al., [@B118]). While further studies showed that the recycling endosomes marker Rab11 is colocalized with internalized BACE1, and the impairment of Rab11 activity caused accumulation of internalized BACE1 in the soma with a concomitant decrease of its expression levels in axons (Buggia-Prévot et al., [@B17]). The newest study revealed that recycling endosomes are the major locale of APP and BACE1 convergence in the dendrites by direct optical assay based on fluorescence complementation, and in the soma, APP and BACE1 interaction at the TGN (Das et al., [@B31]). In summary, the mechanisms are not clear yet. We draw a profile from the discussion above to provide a better reference for others (details see Figure [3](#F3){ref-type="fig"}).

![**Interaction between GPCR and BACE1 in neuronal cell.** Ligand-bind GPCR can activate G proteins and then stimulate downstream signal molecules such as PLC, IP3, AC, and cAMP. IP3 can bind to IP3 receptor in the endoplasmic reticulum (ER) leading the release of Ca^2+^. β-Arrestin can be recruited to GPCR mediating its desensitization, internalization and G protein independent signaling pathway. GPCR, BACE1, APP, and γ-secretase are synthesized in ER, and then be transported into plasma membrane, then be guided to endosome. After that these proteins can be sorted to lysosome, proteasome, ER, or back to plasma membrane. After sequential cut by BACE1 and γ-secretase, APP releases Aβ, which can form oligomers and fibers and finally senile plaque. In addition, soluble Aβ can promote the phosphorylation of tau, which in turn accelerates the aggregation of Aβ. These factors eventually cause the synapse dysfunction and AD.](fnagi-08-00058-g0003){#F3}

Perspectives {#s6}
============

BACE1 has broad biological functions in cells, but in the respect of AD therapy development, scientists are devoted to searching a way of inhibiting its undue cleavage of APP without impacting other substrates that have important physiological functions *in vivo* (Vassar, [@B143]). Likewise, the most severe side effects due to absence of γ-secretase activity are caused by deficient Notch signaling (Selkoe and Kopan, [@B122]). Researchers found that GPR3 apparently affects the processing of APP, but not of Notch, which suggests that GPR3 is an interesting AD therapeutic target (Thathiah et al., [@B138]). However, clinical trials carried out so far have highlighted the difficulties involved in this type of anti-AD therapy. As evidenced by side effects, likely due to the ubiquitous nature of the secretases, it might cleave multiple substrates. Thus, combining potency, selectivity and the desired safety profiles remains to be a continued challenge. Hence, there is still a clear need for a novel biochemical research for the development of potent and selective modulators targeting BACE1 with properties optimal for central nervous system therapeutics (Yan and Vassar, [@B48]). The biased ligands and allosteric modulators of GPCRs provide the promising options (Khoury et al., [@B64]; Violin et al., [@B145]; Luttrell et al., [@B79]).

Biased Ligands {#s6-1}
--------------

Typically, GPCR activation is involved in broad networks of signaling pathways, in which most are mediated by G proteins and β-arrestins (Lefkowitz and Shenoy, [@B76]). Standard agonists and antagonists are able to activate or inactivate the entirety of a receptor's signaling network. However, biased ligands (see Figure [4](#F4){ref-type="fig"}) can selectively engage some signals while avoiding other signaling pathways mediated by the same receptor (Wei et al., [@B151]). Biased ligands provide functional selectivity for pharmacology and gain increasing prominence. A handful of biased ligands that are specifically targeting G protein or β-arrestin signaling pathways have been discovered (Violin et al., [@B145]), among which ligands targeting angiotensin II type 1 receptor, β~2~AR, opioid receptors are the hottest. An example is applying biased agonist pilocarpine in the treatment of AD. Pilocarpine shows positive therapeutic effects in different AD models, specially, pilocarpine biased G~q~ mediates PLC activation over G~s~ medicated AC stimulation, whereas non-selective muscarinic agonist carbachol could equally stimulate G~s~ and G~q~ signaling pathways (Fisher et al., [@B39]).

![**Conventional and Biased ligand-GPCR signal pathway.** In conventional ligand-GPCR signal model, the benefit and side effect are thought to turn on or off at the same time; in biased ligand-GPCR signal model, benefit can be maintained while side effect can be eradicated.](fnagi-08-00058-g0004){#F4}

Allosteric Modulators {#s6-2}
---------------------

Conventional ligands belong to orthostatic GPCR agonists, and their cellular effects are mediated through interacting with the ligand-binding pocket and changing the distribution of conformation within the receptor ensemble. Allosteric modulators include ions, ligands, small and large molecules and protein complexes that modulate the coupling of receptors to their effectors by binding to GPCRs at a site other than the protein's active sites, which are endogenous ligand binding sites. The conformational change caused by the allosteric ligands can selectively alter the reactivity of the receptor towards certain aspects of the pharmacology of the orthosteric ligand but not others, which engendered stimulus-bias. According to the effects on receptor signaling, allosteric ligands have been divided into two main categories: positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs; Khoury et al., [@B64]). Two drugs have been launched: Sensipar/Mimpra cinacalcet (Amgen/NPS) is a PAM of calcium-sensing receptor (CaSR) for hyperparathyroidism treatment; Selzentry/Celsentri maraviroc (Pfizer) is a NAM of C-C chemokine receptor type 5 (CCR5) for human immunodeficiency virus (HIV) therapy. Much work has been done to screen the biased allosteric modulators for treatment of AD, among which, modulators targeting mAChRs lead the research. MK-7622 from Merck is a PAM of M~1~ receptor that is currently tested in phase II (Conn et al., [@B29]). The M~1~ AChR agonist AF267B can alleviate pathology of AD by shifting the processing of APP towards the non-amyloidogenic pathway (Caccamo et al., [@B19]). TBPB, a systemically M~1~ AChR allosteric agonist, was shown to decrease the level of APPβ (Jones et al., [@B60]). Data from early optimization and animal studies are indicative of a healthy pipeline of novel allosteric modulators that hold promise for the treatment of AD (Caccamo et al., [@B19]; Jones et al., [@B60]; Conn et al., [@B29]).

Concluding Remarks {#s7}
==================

Collectively, AD is a complex disease and regarding the reported factors, one solution might not be enough to deal with the complex condition *in vivo* (Thathiah and De Strooper, [@B135]). It is clear that several GPCRs and GPCR related proteins are involved in the regulation of BACE1 and the pathogenesis of AD (Table [2](#T2){ref-type="table"}). Nevertheless, progress in this field is hampered by the difficulties in screening ligands with high specificity and selectivity and by the adverse side effects of drugs in the pipeline. Studies have demonstrated that BACE1 and γ-secretase have other necessary functions in cells, simple segregation of these secretases will cause a hamper of their ordinary functions and lead to undesirable side effects, which are so overwhelming that they prohibit drug's efficacy and approval. There is an urgency to understand mechanisms involved in how GPCRs mediate secretases in AD. According to the literature, GPCRs might regulate the secretases via G protein-dependent signaling pathways, or influence the degradation and internalization of secretases. However, this area is still filled with unsolved problems that need to be determined by further investigations. With the development of biased ligands and allosteric modulators of GPCRs, the therapeutic potential of GPCRs might be enhanced to provide alternative strategies for effectively modulating AD pathogenesis with fewer side effects in the future.
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